GlobeNewsWire
30 Jul 2026, 11:35 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Crescent Biopharma completed a $143.7 million public offering, extending its cash runway into the second half of 2028. — Securing funding beyond key clinical catalysts significantly reduces the immediate risk of bankruptcy or dilutive emergency financing.
+0.60Multiple key clinical data readouts across the company's oncology portfolio are expected to begin in Q1 2027. — Provides a clear timeline for value-inflection events, though the dates are distant enough to limit immediate price volatility.
+0.40The company is initiating a global Phase 1/2 trial for CR-002, a PD-L1-targeted ADC, in the second half of 2026. — Expansion of the clinical pipeline into a new global study represents progress in pipeline diversification and growth.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Net loss for the second quarter of 2026 was $24.8 million, an increase from $21.8 million in the prior year period. — While losses are increasing, this is typical for clinical-stage biotech firms scaling up R&D and is expected by investors.
-0.10Which stocks this story touches
The company reported positive clinical trial progress and successfully completed a $143.7 million public offering extending its cash runway into 2028.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Invezz
1h ago
